DBV Technologies
http://www.dbv-technologies.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DBV Technologies
Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval
Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week.
DBV Pulls EU Peanut Allergy Patch Filing To Work On A Stronger Application
Following regulatory setbacks in the US and also now in the EU, DBV Technologies is to conduct a new pivotal trial of a modified version of its peanut allergy patch to support its efforts to win marketing approval.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
- Transdermal
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice